Deal Delays Generic Lipitor Until 2011

Pact with Indian drug maker stands to net billions for Pfizer
By Sam Gale Rosen,  Newser Staff
Posted Jun 18, 2008 5:11 PM CDT
Deal Delays Generic Lipitor Until 2011
Forty-milligram tablets of the drug Lipitor are photographed in Glen Rock, N.J., in a file photo from Nov. 15, 2005.   (AP Photo/Mel Evans, File)

Pfizer has struck a deal with an Indian generic drug maker to delay a cheaper version of Lipitor in the US until November 2011. The agreement limiting generic versions of the cholesterol-lowering drug will translate into billions more in profits for Pfizer, the New York Times reports. Lipitor, the world's best-selling medicine, costs about $3 a day; a generic version will likely be less than $1.

Pfizer's counsel calls the agreement “pro-patient, pro-competition, and pro-intellectual property.” But not everyone agrees. “This is clearly a miscarriage of the law,” says one analyst. Pfizer will not pay Ranbaxy—the Indian drug maker—but will allow it to sell generic Lipitor in a number of countries outside the US. The Federal Trade Commission is not expected to challenge the agreement. (More Lipitor stories.)

Get the news faster.
Tap to install our app.
Install the Newser News app
in two easy steps:
1. Tap in your navigation bar.
2. Tap to Add to Home Screen.